January 2018 Event Report - Wild Apricot · Phylos Bioscience Kannaway/M3 Consulting Medwell Health and Wellness Center Revolutionary Clinics 8:45 - 9:00 Networking Session Talks

Cannabis Community Care and Research Network January 2018

2018 Cannabis Science, Education, and Networking Series

January 2018 Event Report

How Can We Advance Cannabis Research in Massachusetts?

Opportunities for cannabis cultivation, laboratory, clinical, social, and public health research

Held on January 25, 2018 6:00 – 9:30 PM

Canopy City Co-Working Space, 14 Tyler Street, Somerville, MA 02143

Hosted by

Cannabis Community Care and Research Network (C3RN)


Table of Contents About Cannabis Community Care and Research Network (C3RN) ………………………………1 Thank You to Our Sponsors………………………………………………………………….………..2 January Event Schedule…………………………………………………………………….…………4 C3RN and Establishing a Virtual Cannabis Center of Excellence…...…………………….……...5 Text Polling………………………………………………………………………….…………………...6 Speaker Presentations…………………………………………………………………………............8 William Luzier……………………………………………………………………………..........8 Staci Gruber, PhD………………………………………………………………………………9 Nichole Snow…………………………………………………………………………………..11 Michael Kahn…………………………………………………………………………………..12 Meghan Miller………………...........................................................................................13 The Clinical and Public Health Impacts of Medical Cannabis Use Overview……………….......14 Interactive Education Station Abstracts………………………………………………………..........16 Elite Phenos……………………………………………………………………………………16 The Healing Rose……………………………………………………………………………...19 M3 Consulting………………………………………………………………………………….20

MCR Labs……………………………………………………………………………………...22 Phylos Biosciences…………………………………………………………………..………..23

Revolutionary Clinics……………………………………………………………………........25 February Event: Community First in Cannabis!.....…………………………………………………26 Full Event Series Details………………………………………………………………………………27 References Cited………………………………………………………………………………………28


1

About Cannabis Community Care and Research Network (C3RN)

Cannabis Community Care and Research Network (C3RN) is a Massachusetts-based research company that specializes in providing high-quality research and analytic services related to the impacts of medical and adult-use recreational Cannabis. As a social justice-oriented company, we specialize in designing, monitoring, and evaluating models of integrating adult-use and medical Cannabis to positively impact social, clinical, and public health outcomes. Our goal is to support the development of a Center of Excellence in Massachusetts that advances the scientific evidence-base for medical and legal Cannabis in the Commonwealth and beyond. For more information about our work and services, please visit: www.cannaresearchnetwork.com and www.cannacenterofexcellence.org Marion McNabb, DrPH, MPH, CEO and Founder [email protected] and Randal MacCaffrie, Creative Director and Founder [email protected] Acknowledgements This report related to advancing research for medical and adult-use Cannabis was prepared for the attendees of C3RN’s launch event for the Cannabis Science, Education, and Networking Series. Special acknowledgements go to Marion McNabb, DrPH, MPH; Margaret D’Elia, MPH, and N.B. Arora, PhD for authoring this report.


2

Thank You to Our January Event Sponsors This event would not have been possible without the support from our sponsors! Thank you for supporting the vision to advance dialogue and opportunities, and to increase the evidence-base around cannabis and its impact on clinical, social, and economic outcomes. Special thanks to New England Treatment Access (NETA), MCR Labs, Green Lion Partners, Phylos Bioscience, and Seaweed Technologies for the financial support to make this event possible!

THANK YOU FOR THE SUPPORT TO ADVANCE CANNABIS SCIENCE!


3

Thank you also to the many in-kind sponsors who supported the production of the event, we thank you for the support! Thank you to Mass Cannabis Chefs for the incredible non-infused food and catering the event – the food was spectacular! Big thanks to Boneup Brewing Company for sponsoring the delicious beer! Did you enjoy the music? Thank you to DJ Skotvoid for the networking music, and to Mikes Music, Inc for the audio visual set up and lighting for the event! Thank you also to 13 FOLDS magazine for the support with discounted printing for the event.


4

2018 Cannabis Science, Education, and Networking Series January 25th, 2018 6-9:30pm

Event Schedule 6:00 – 6:45 Registration and Networking 6:45 – 8:00 Panel Discussion

Dr. Marion McNabb - CEO, Cannabis Community Care and Research Network (C3RN)

William Luzier - Political Director, Yes on Question 4

Staci Gruber, PhD - Director, Cognitive and Clinical Neuroimaging Core, McLean Hospital, Director, Marijuana Investigations for Neuroscientific Discovery (MIND), Associate Professor of Psychiatry, Harvard Medical School

Nicole Snow - President and Executive Director, Massachusetts Patient Advocacy Alliance (MPAA) Michael Khan - President and Founder, MCR Labs Meghan Miller - VP of Global Partnerships, Phylos Bioscience

8:00 – 8:45 Interaction Education Station Networking

MCR Labs The Healing Rose Elite Phenos Phylos Bioscience Kannaway/M3 Consulting Medwell Health and Wellness Center Revolutionary Clinics

8:45 - 9:00 Networking Session Talks

Nadir Pearson - Founder/President, Student Marijuana Alliance for Research & Transparency (SMART) Beth Waterfall - President and Founder, ELEVATE New England Sonia Espinosa and Kamani Jefferson, Massachusetts Recreational Consumer Council (MRCC)


5

C3RN and Establishing a Virtual Cannabis Center of Excellence

The evening started out with a presentation by Dr. Marion McNabb, co-founder and CEO of Cannabis Community Care and Research Network (C3RN). C3RN is a cannabis research and education startup company based out of Massachusetts. C3RN was formed in early 2017 in response to the historical difficulties U.S.-based researchers have faced in conducting cannabis research studies and clinical trials. Due to the Federal scheduling of cannabis as a Class 1 substance, researchers are forced to comply with restrictive regulations and a lack of funding to rigorously study the medical and social impacts of cannabis. This has resulted in lack of clinical trials and other rigorous study designs of the health impacts of cannabis as it relates to specific health conditions. With a dearth of scientific evidence in the peer-reviewed literature, healthcare providers are also largely unaware of the potential medical benefits of cannabis. In November 2016, the majority of Massachusetts residents voted Yes on Question 4 to legalize the adult-use cannabis in the Commonwealth. Over the last year the Cannabis Control Commission (CCC) was formed and the draft regulations for the adult use cannabis industry were published in December 2017. A research license category was included in the draft regulations which offers great opportunity to bring together clinicians, researchers, cannabis industry experts, and policy makers to develop a community that is interested in advancing Cannabis research. It is with this in mind that C3RN launched a six-month cannabis science, education, and networking series to create a space for open and honest dialogue about how to advance cannabis research. Dr. McNabb re-iterated that these events are meant to be collaborative, open spaces to generate dialogue and discussion to further the research agenda. Throughout this first event, attendees were asked to participate in a number of text polling questions. The introductory question, the question that will be asked at each event, is presented below with results.


6

Text Polling

Of the 45 total respondents, 15 (33%) were most interested in Cannabis Cultivation & Processing Practices, 15 (33%) were most interested in Medical Cannabis & Impact on Health, 5 (11%) were most interested in Cannabis & the Opioid Epidemic, 4 (9%) were most interested in Adult-Use Cannabis, 4 (9%) were most interested in Social Justice & Equity, and 2 (4%) were most interested in Public Safety, Impaired Driving, & Youth Prevention.


7

Of the 65 total respondents, 30 (46%) believe Chronic Pain has the most scientific evidence for medical cannabis, 12 (18%) believe Cancer has the most scientific evidence for medical cannabis, 10 (15%) believe Glaucoma has the most scientific evidence for medical cannabis, 5 (8%) believe Crohn’s Disease has the most scientific evidence for medical cannabis, 3 (5%) believe Multiple Sclerosis has the most scientific evidence for medical cannabis, 3 (5%) believe Lou Gehrig’s Disease (ALS) has the most scientific evidence for medical cannabis, 1 (2%) believe Parkinson’s Disease has the most scientific evidence for medical cannabis, and 1 (2%) believe HIV/AIDs has the most scientific evidence for medical cannabis. Following the text polling, the expert speakers covered topics related to their expertise. The following section is a summary of their presentations.


8

Speakers

William Luzier, Political Director Background Will Luzier is a former Massachusetts assistant attorney general who also served as executive director of the Massachusetts Interagency Council on Substance Abuse and Prevention from 2008 until April 2015. In 2015, Will was named as campaign manager for the Yes on 4 Campaign. He now serves as the political director for the Marijuana Policy Project in Massachusetts. Event Will offered an update regarding the current state of affairs related to cannabis laws in Massachusetts. His presentation came only weeks after U.S. Attorney General Sessions rescinded the Cole Memo which directed federal authorities not to interfere with state authorized cannabis programs. Following Session’s actions U.S. Attorney Lelling, who oversees Massachusetts, released a statement that he would not rule out the possibility of prosecuting state authorized cannabis businesses. Will, in response to the federal government’s actions, helped to conceive the “Refusal of Complicity Act” which seeks to prohibit state law enforcement officials from assisting federal authorities with prosecution of state authorized cannabis businesses. Call to Action Now more than ever, given the climate at the federal level, it is important for citizens of Massachusetts to make their voices heard regarding cannabis laws. The Cannabis Control Commission (CCC) held the final set of public hearing sessions at locations across the commonwealth from February 5 – 13, 2018. The CCC wants to hear from citizens so it is important that community members stay up to date with happenings at the CCC. More information can be found here: https://www.mass.gov/orgs/cannabis-control-commission.


9

Staci Gruber, PhD, Director, Cognitive and Clinical Neuroimaging Core, McLean Hospital; Director, Marijuana Investigations for Neuroscientific Discovery (MIND); Associate Professor of Psychiatry, Harvard Medical School Background Dr. Gruber’s clinical and research focus is the application of neurocognitive models and multimodal brain imaging to better characterize neurobiological risk factors for substance abuse and psychopathology. Dr. Gruber’s lab has examined the etiologic bases of neural models of dysfunction in patients with psychiatric disorders as well as marijuana-abusing adults. She has published in numerous journals and been the focus of national and international symposia and press conferences. She also directs the MIND program, designed to clarify the effects of recreational and most recently, medical marijuana on brain structure, function, and quality of life. Event Looking back in history humans have been using cannabis for quite some time. Cannabis was included in the United States Pharmacopeia for nearly 100 years, before removal in 1942. Despite this exclusion cannabis has still become medically legal in some form in 30 states and recreationally legal in eight states. Washington D.C. has also legalized both medical and recreational use. Dr. Gruber is the founder of the Marijuana Investigations for Neuroscientific Discovery (MIND) program and has authored or co-authored 14 peer reviewed journal articles describing her research. Dr. Gruber shared some of the key findings of her research including: (1) Neurocognitive decrements are most commonly observed in early onset users, with adult onset users having a significantly lower rate, (2) Comparison of medical and recreational cannabis users has shown important differences related to reason for use, molecular constituents of preferred products, and age of onset, and (3) Longitudinal, observational studies with cannabis users have shown improvements in mood, quality of life, and executive function. Participants also showed reduction in use of opioids and benzodiazepines. Dr. Gruber also highlighted key findings from The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (NASEM, 2017). Findings included: (1) Conclusive or substantial evidence supporting efficacy of cannabis as a treatment for chronic pain, chemotherapy-induced nausea and vomiting, and multiple sclerosis spasticity. Very severe child seizure disorders may also be added to this list in the near future and, (2) Other conditions require further research to draw evidence-based conclusions.


10

Call to Action More cannabis research is crucial to answering key questions in the field. The MIND program is currently performing studies on use of CBD for treatment of anxiety and observational studies of veteran cannabis users. Dr. Gruber described several other areas in need of more research including mode of use, cannabinoid profile and associate impacts, clinical indications for use, impact of higher potency products, most efficacious strains, possibility of harm reduction, and lab testing improvements. To overcome research barriers such as federal scheduling and funding issues the cannabis community must work together and think creatively to solve research problems.


11

Nichole Snow, President and Executive Director, Massachusetts Patient Advocacy Alliance (MPAA) Background After meeting hundreds of patients across the state of Massachusetts and advocating for their right to safe access, Nichole was invited to take a leadership role in the MPAA. Since becoming director of the fledgling organization, Nichole worked with all stakeholders involved in the implementation of the Humanitarian Care Act of 2012 to implement viable regulations, site over 100 safe access points across the Commonwealth, and grow the number certified patients from 153 in October of 2014 to a total of 39,873 as of February 2017. Event Nichole introduced the Massachusetts Patient Advocacy Alliance (MPAA) and described their mission and some of the problems still confronting medical patients in MA. MPAA is an organization focused on providing non-biased resources to both individuals and organizations seeking to learn about medical cannabis. They also work to ensure the social welfare of all stakeholders in the medical cannabis space. While medical cannabis is regulated and available to patients Nichole identified areas where there is still progress to be made. This includes patients’ right to access their medicine when and where they need it and improving safety and availability of products currently on the market. MPAA have been appointed as permanent advisors to the Cannabis Control Commission and continue to advocate for patients’ rights across Massachusetts. Call to Action There is concern among those involved with medical cannabis that the growth of the recreational cannabis industry in Massachusetts may detract from the gains medical patients and the medical program as a whole has made over the past several years. MPAA launched the Medical Marijuana First program with the mission of protecting patient’s needs and providing education to the community on this topic.


12

Michael Kahn, President and Founder, MCR Labs Background With over 10 years of experience in the pharmaceutical and academic research fields, Michael brings a wide range of laboratory and teaching experience to MCR Labs. Michael has been an advocate for product safety and efficacy through reliable testing in the cannabis industry. He has spoken publicly for the right of medical cannabis consumers to access testing results that current scientific practices can provide. Event Michael stressed the importance of testing cannabis for potency and safety. This type of testing demonstrates integrity of the product to patients, supports product development efforts, and reduces incidences of contamination. The Massachusetts Department of Public Health (DPH) mandates that all products are tested for cannabinoid potency, heavy metal contamination, pesticide residue, toxin contamination, microbial contamination, and residual solvent. Data from MCR Labs shows that cannabis flower from Registered Medical Dispensaries (RMD) has a higher pass rate in all categories than flower obtained from non-RMD sources. This demonstrates that RMDs are motivated to comply with DPH regulations and that these regulations result in medical patients receiving access to safe products. Call to Action Michael highlighted a few important gaps in the current medical cannabis marketplace. The first is that cannabis has not been clearly classified as a pharmaceutical, food, supplement, or nutraceutical. This causes ambiguity related to the future of testing and regulation requirements. The second is the lack of consistent data feedback loops in the cannabis market. Unlike traditional pharmaceuticals, where patient data is constantly collected and used to make product adjustments and improvements, the cannabis market has relatively little customer, analytical, or quality control data coming back to the companies that provide products. Both of these issues need to be addressed before major advancements in cannabis testing can be made.


13

Meghan Miller, Vice President of Global Partnerships, Phylos Bioscience Background Meghan’s career has covered nearly 15 years of record achievement as a sales innovator, collaborative partner, business developer, product/process evangelist and trusted advisor to her customers and colleagues alike. Event Meghan focused on a major issue in the medical cannabis industry, consistency of the products. It is common for products bearing the exact same cannabis strain name to exhibit different properties and therefore give users a variable experience each time. This is an issue because when a patient finds a strain that relieves their symptoms they seek that relief on a consistent basis. The way to solve this problem is to better understand the genetics of the cannabis plant and use that understanding to improve consistency of products for patients. Phylos Bioscience is a plant genetics company concentrating specifically on cannabis. They have sequenced thousands of varieties of cannabis genotypes. All the data is freely available and easy to visualize using the Galaxy, created by Phylos. Call to Action Phylos Bioscience is a founding member of the Open Cannabis Project. The goal of the project is to build an archival record of all existing cannabis strains and genotypes. This data is freely available to anyone and will always remain so. Cultivators and others in the space are encouraged to contribute in order to advance the understanding of cannabis for all.


14

The Clinical and Public Health Impacts of Medical Cannabis Use Overview

What is the Evidence Surrounding Medical Cannabis Use? The medical use of Cannabis is now widely accepted in the United States with 29 states, the District of Columbia, Guam, and Puerto Rico allowing its use for a wide range of health conditions.1 As of 2017, there are an estimated 2.3 million medical Cannabis patients in the United States.2 The evidence base related to medical Cannabis is growing. In January 2017, The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, was published by the National Academies of Sciences, Engineering, and Medicine. The report provides the latest evidence available around the medical benefits of cannabis use. The following are the most up to date findings regarding cannabis use available.3 There is conclusive or substantial evidence that cannabis or cannabinoids are effective in the treatment of:3 • chronic pain in adults • as an antiemetic in the treatment of chemotherapy induced nausea/vomiting • improving patient-reported multiple sclerosis spasticity symptoms There is substantial evidence of a statistical association between cannabis use and:3 • increased risk of a motor vehicle crash (MVC) • the development of schizophrenia or other psychoses There is moderate evidence of a statistical association between cannabis use and:3 • better cognitive performance among individuals with psychotic disorders • increased incidence of social anxiety disorder • increased incidence of suicide contemplation There is limited evidence of a statistical association between cannabis use and:3 • the triggering of an acute myocardial infarction • risk of ischemic stroke or subarachnoid hemorrhage • risk of prediabetes • risk of developing chronic obstructive pulmonary disorder (COPD) • impaired academic achievement and education outcomes • increased rate of unemployment and / or low income • impaired social functioning in developmentally appropriate social roles • increased symptoms of anxiety • increased severity of posttraumatic stress disorder symptoms • initiation of tobacco use There is insufficient or no evidence of statistical association between cannabis use and:3 • death due to cannabis overdose


15

There is moderate evidence to support the lack of statistical association between cannabis use and:3 • the incidence of lung, head, and neck cancer • worsening of negative symptoms of schizophrenia among individuals with psychotic disorders Medical Cannabis and the Impact on the Opioid Epidemic The scientific evidence supporting the positive effect of Cannabis for the treatment of opioid addiction and chronic pain is well established.4 Several studies have documented a range of 31% - 80% of medical patients reporting successfully substituting cannabis for opioids and other prescription medications.4-5 Three separate but recent studies also show that states with medical Cannabis laws have also seen from 13% - 35% significant reduction in opioid overdose deaths compared to states without. 6-7 Due to increasing evidence that Cannabis can have an impact on opioid addiction and recovery, in September 2016, the CDC published new guidelines for opioid addiction and recovery treatment programs calling for clinicians to stop Cannabis (THC) drug testing as a requirement for their treatment. The guidelines also urge doctors not to drop patients who test positive for THC.8 The cost savings related to integrating medical cannabis is also compelling. A recent study reviewed Medicare Part D prescriptions enrollees from 2010 to 2013 and found that prescription drug use fell significantly for those medications that Cannabis could serve as a clinical alternative. Additionally, national reductions in Medicare spending when States implemented medical Cannabis laws were estimated to be $165.2 million per year in 2013.9 These findings suggest that State and private insurance companies could save hundreds of millions of dollars that they would normally payout to cover thousands of these prescription medications.10


16

Interactive Learning Stations

In the spirit of hosting a Cannabis “Science Fair” each vendor was asked to identify an interesting piece of science related to their work. Each group prepared an “Abstract” that describes their work, what sets them apart, and what future research questions they may have. The following are the interactive learning station abstracts: Vendor | Elite Phenos Science | Horticulture Abstract Commercial Cannabis Breeding: “Throwing pollen in the wind” Author: Douglas Klier M.A. Introduction Elite Phenos is a minority owned, family-run business. We strive to identify and maintain the highest level of genetics through selective breeding and mother plant identification for commercial cannabis sales. We will meet the demand for premium cannabis and secure a significant market share within the Commonwealth producing craft cannabis. Background Commercial cultivators are constantly challenged to identify unique phenotypic expressions from known strains that are the desired medicinal and recreational representations of their genotype. This challenge is significant due to the novelty and lack of therapeutic focus and horticultural breeding practices by seed companies. This absence of education, transparency, and documentation and records has resulted in and unpredictable genetics and an endless amount of genetic variation. This is a major barrier in working with providers and patients to alleviate symptoms and curative practices with cannabis.

Most seeds companies only produce “feminized” seeds. The purpose of this is to protect their genetics and to meet the demand for the home grower, where males are seen to be undesirable. This process is done by daily spraying of the female plant at early flower sites with Colloidal Silver, causing the plant to display hermaphroditic properties and self-pollinate. Elite Phenos has been able to collect 25 unique phenotypic representations over the last 17 years that are maintained as Mother Plants for breeding with select males towards stabilizing medicinal and beneficial properties. These properties will be genetically selected and emphasized through (ILB) In-line Breeding.


17

Methods The soil system mimics an outdoor growing environment, making for an ideal ecosystem in which cannabis plants can thrive, unlike the common hydroponic and synthetic systems found in a majority of growing facilities across the United States today. The soil is living, meaning there are thousands of microbes milling around in the soil. Microbes are beneficial microscopic bacteria that aid the cannabis plants with nutrient uptake from the soil. Cannabis plants have evolved over thousands of years to actively communicate with these microbes. With living soil, you are allowing the plant to naturally choose when and what to eat, whereas in a hydroponic or synthetic system you force-feed the plant. Plants reach their highest potential, in terms of terpene and cannabinoid production, when you allow them to feed naturally. We use pure organic nutrients in proper amounts to ensure the plant is fed properly until harvest. We test the soil to note the nitrogen, phosphorus and potassium levels are optimal for each crop. We add organic nutrients based on the soil's needs. These nutrients are bat guano, alfalfa meal, granular humic acids, limestone, and kelp meal. Elite Phenos is committed to reducing our carbon footprint and utilizing organic practices that are sustainable and responsible to the environment. In 2016 Elite Phenos purchased and installed a 15.65 kW solar system consisting of 60 panels. Solar electric technologies were purchased to reduce our electricity bill, generate clean power for our business and empower us to be more energy independent. Our system produces more than 1,000kwh monthly with a carbon offset of 1,300 lbs or 16 Trees! Results The strain below emerged from the Humboldt County, CA (area code 707). It is a cross between Sour Diesel, OG Kush, and Master Kush. 707 Headband plants flower in 9-11 weeks and usually have large yields. An indica dominant hybrid, this strain is known to have high THC levels and can be strong, but it is balanced enough to leave most users feeling “heady” and creative rather than sleepy. Because of this, it’s often used to treat tension and anxiety. Medicinal properties of the strain are used to treat: pain, stress, depression, nausea, and fatigue. Below are two distinct phenotypes from the same strain. Both of these plants are the same age (55 days) and were germinated from seeds from the same genetic parents. Phenotype #1 presents with an exceptional purple hue throughout her vegetation and a terpene palette that smells of “starburst”. She is an above average yielder and differs from her sister by internodal spacing, flower structure and calyx to leaf ratio. Phenotype #2 presents with a traditional green color and smells of “Pledge” and a fuel smell, showing a dominant genetic lean towards her Sour Diesel parent. She is a heavy producer and has extremely dense cola structure.


18

Phenotype #1 Phenotype #2 Conclusion Elite Phenos has averaged approximately 500 traditional seeds to identify and isolate 1 unique phenotypic expression that is the best representation of its genotype without also possessing undesirable characteristics and side effects.


19

Vendor Name | The Healing Rose Science | Handcrafted Organic Salves Introduction The Healing Rose Company creates hemp-derived CBD infused body care products here in Massachusetts. Products are created in small batches using natural and organic ingredients such as organic herbs and essential oils combined with 100% THC-Free Phytocannabinoid Rich Hemp Oil. These formulas have been developed over countless hours and through ongoing research and development. Methods If we are creating a Peppermint Spice Extra Strength Salve, we would use the following, all organic, ingredients: shea butter, coconut oil, beeswax, mango butter, jojoba oil, arnica extract, calendula extract, non-GMO vitamin E oil (tocopherol), clove oil, ginger oil, peppermint oil, and phytocannabinoid rich CBD hemp oil. Our process starts with preparing the workspace. We clean and sanitize the environment as well as any tools we may use. We then weigh out our butters and oils. Using heat to melt the oils and butters, we homogenize our materials. Once the heat is at the optimal level, we remove the mixture from the heat and add in our heat sensitive ingredients. Finally, we pour the mixture into sterilized containers and cap them prior to labeling, wrapping, and packing them. Results and Discussion When preparing these products, it is imperative that we record everything. This allows us to maintain quality standards as well as ensure consistency throughout our products. We weigh every material and strive to maintain homogenization through batch testing. Our final product is a result of carefully screened and measured ingredients, as well as finding optimal ratios of ingredients. Each of our products is organic and natural, ensuring the highest quality possible.


20

Vendor Name | M3 Consulting

Science | Kannaway

Introduction Educate about the uses of cannabis and the reintroduction of hemp into American culture. Background / Problem "All 48 states then had legislation to control the cultivation of cannabis, but the production and use of marijuana was still not prohibited by federal law. The fear persisted that any federal drug law might be ruled unconstitutional. The Marihuana Tax Act of 1937 was therefore modeled on the Harrison Narcotics Act, as well as on a more recent act restricting gangsters from using machine guns by requiring them to pay a transfer tax."1 Thus began the prohibition of cannabis in the United States. Now it is 2018 and drug overdose deaths, especially opioid related deaths are at an all-time high.2

Cannabis remains a schedule 1 substance, "Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse." 3

How can we as a community end this prohibition and allow for medical research, along with agricultural advancements? I believe that only through education and the reintroduction of cannabis products into mainstream culture will this be a reality at a national level.

CBD Hemp Oil / Hemp Products are a way to introduce a large number of people to cannabis products while remaining within current state and federal regulations. Going forward in the ever-changing cannabis environment, there will always be a need for CBD products for those who enjoy the effects of cannabis other than the psychoactive.

1 https://www.dea.gov/about/history/Early%20Years%20p%2012-29.pdf / pg.19 2 https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates 3 https://www.dea.gov/druginfo/ds.shtml


21

Methods "Kannaway’s Hemp Oil is derived from legal non-GMO European industrial hemp, utilizing our proprietary extraction methods to extract the hemp oil from the mature stalk. The key to our proprietary extraction method is to achieve an “essential plant complex”, which is rich in cannabinoids, terpenes, flavonoids, waxes and chlorophyll that are essential to the human body. To ensure our products will meet the highest quality standards, each batch of hemp oil undergoes our Triple Lab Testing™, which includes 3 separate tests of your product between harvest and final packaging."4

Results Product line has become the first international cannabis company with offices in United States and Europe.5 Conclusion In the future I hope that more discussion will be allowed regarding the benefits and effects of cannabis products. Not just as health care supplements.

4 https://kannaway.com/kannaways-hemp-oil/ 5 https://kannaway.com/7619547/


22

Vendor Name | MCR Labs Science | The Cannabis Review Introduction The cannabis plant has been widely used for centuries to treat ailments and alleviate symptoms across the world. As states and countries implement medical and recreational cannabis policies, increasing numbers of people are exploring cannabis-based pharmacotherapy options. The goal of this review is to aggregate relevant studies into one database where researchers, patients, and doctors can easily access the data and information necessary to understanding the scope of research conducted on cannabis and the molecules found therein. Methods An extensive search of trustworthy scientific publications was conducted to identify studies on the medicinal properties of cannabinoids and terpenes found in cannabis. 372 scientific studies were considered for this systematic review, of which 125 are related to cannabinoids and 247 to terpenes. The studies were given a grade of 1 to 4 based on the methodology with 1 being the lowest grade and 4 the highest. A magnitude of effects (minor, moderate, and major) was also identified for each study’s findings. Results and Discussion The results of our review indicate there is significant evidence that cannabis and the molecules found within have many medical benefits and potential applications. Sixty-seven (67) scientific studies showed moderate to major anti-inflammatory effects used in the treatment of edema, arthritis, neuroinflammation, colitis, and retinal inflammation. Thirty (30) studies showed that cannabis compounds have strong antimicrobial properties by inhibiting growth and proliferation of various bacterial and fungal strains. Twenty-nine (29) studies identified the antioxidant properties of cannabis compounds that fight oxidative stress-related illnesses. Twenty-four (24) studies showed the anticancer properties used to treat and prevent the proliferation of a wide variety of cancer including breast, prostate, cervical, colon, liver, and glioma carcinoma. Twenty-one (21) studies showed antibacterial and antifungal properties of cannabis compounds. Conclusion We have collected a substantial amount of evidence that supports the medicinal potential of cannabis and the need for further research. This database is a resource for patients, doctors, and researchers that enhances the availability of information and facilitates the expansion of the knowledge base. While we understand that we have not yet collected all the relevant studies, it is evident that the scope of studies performed on cannabis and the molecules therein is limited. Our hope is that this review will serve as a tool for legitimizing cannabis in the eyes of the medical community and the public at large and will lead to an increase in future studies being performed.


23

Vendor | Phylos Bioscience

Science | Cannabis Genomics

Introduction At this time Phylos Bioscience has the largest database of cannabis DNA in the world. As we continue to collect more data, we begin to better understand how domestication affected the lineage of the plant. We also help cultivators grow better cannabis by providing them insight into the genetic makeup of their plants. What does the Galaxy tell us about cannabis genetics? 1.) There’s lots of genetic diversity 2) How varieties are related to each other. 3) Variety (strain) names are often ambiguous / same name many places on galaxy 4). Some samples are genetically identical but given different names. 5) Which varieties are more genetically stable inbred and will produce consistent offspring with trait persistence. Phylos will provide a visual presentation of the Phylos Galaxy. Because we believe in open data, we make our data publically accessible via the Open Cannabis Project. We will review how we use our 3D visual model of DNA to explain how cannabis plants are related to thousands of others. Phylos will also walk through specific variety (strain) examples as well as review a Genotype Report (the DNA report of a variety) and what its implications mean for identification and breeding. Background/Problem Cannabis has been domesticated by humans for thousands of years. Now, emerging out of an underground industry, we have the ability to use science to better understand the plant. Phylos Bioscience first explored working with the cannabis genome back in 2014 by collaborating with the Museum of Natural History on a 2 year project. In this collaborative endeavour, we went around the world collecting as many samples as we could. Once collected, we used our 3-D visual model, the Galaxy, to map the data. We have variety samples from over 80 different countries and thousand of varieties mapped on the Galaxy. Our decision to make our data public was founded on the idea that we should preserve plant diversity and help growers defend against false patent attempts. By allowing the Galaxy’s genetic information to be shared with the Open Cannabis Project, we ensure that what belongs in the public domain, remains that way. Methods Phylos Bioscience used Next Generation Sequencing technology along with a proprietary process to extract DNA from plant material. Results


24

The more genetic information we collect, the more we understand how varieties are related to each other. Currently Phylos has over 3,000 cannabis samples on the Galaxy. And we continue to add more data every month. We’ve traveled the world collecting variety samples. Conclusion We are just beginning to understand the cannabis genome. There is such an opportunity to explore and better understand this plant. We will continue to work with breeders and growers by supporting their R&D and breeding programs with our science. Knowing the genetics of a variety will help with patient outcomes. If the genetics of a variety are unknown and a patient is sold a different product with a similar chemical profile, it could affect the patient. Today, we do not understand the entire profile of cannabinoids and terpenes in any one plant. Most chemical analysis focuses on the major cannabinoids and may not test all the relevant ones. If a patient knows the genetic background of a plant, they can be confident of getting the same thing over and over again. Phylos is often asked, can the Galaxy index and predict Phenotypes and Chemotypes? Currently, we only have genetic information and no phenotypes. As we collect data on pheno/chem, we could begin to predict these things for new varieties and help breeders choose parents with certain genetic backgrounds for breeding. We will soon make it possible for sample submitters to add chemotype data to their Galaxy profiles.


25

Vendor Name | Revolutionary Clinics Science | Vaporizing Accessories Introduction Vaporizing is a game changer for people who do not want to smoke cannabis. It is a healthier alternative that can be slightly overwhelming if you don't know what to look for. Background /Problem Certain medical marijuana patients either don't want or can't smoke cannabis for a variety of reasons. Vaporizing offers a healthier alternative that can give patients the relief they are seeking. Method We will be showcasing some of the different vaping/vaporizer options available at Revolutionary Clinics. Result We want to show that vaping/vaporizing is a better way to consume cannabis. It is a cleaner high, there are fewer carcinogens, and less heat is needed to vape. Conclusion Healthier, happier medicated patients.


26


Community First in Cannabis!

Models and best practices for ensuring equitable engagement, access, consumption, and integration in the Cannabis industry in Massachusetts

Cannabis Science and Skills Fair

February 26, 2018 6:00 - 9:30 PM Roxbury Community College, Media and Arts Center

Event Ticket: $60 + free Cannabinoid and Terpene profile lab test* Five-event package: $250

* tests courtesy of MCR labs and Seaweed technologies Students, patients, nonprofits, seniors, and startups get 40% off!

Learn More to Register: http://cannacenterofexcellence.org/register

Age 18+ only; No cannabis will be consumed at the event Dress code business casual, dress to impress!

Shaleen Title - Commissioner, Massachusetts Cannabis Control Commission

Shanel Lindsay, JD - Founder and President of Ardent Cannabis, Advisory Board Member, Massachusetts

Cannabis Control Commission

Sonia Espinosa - Co-founder Massachusetts Recreational Consumer Council (MRCC)

Ellen Brown, President, Sinsemilla Seminars

Eric Martin, Former NFL Patriots Player

Steve Mandile, Veterans Alternative Healing, Inc.

Event Schedule 6:00 – 6:45 Registration and Networking 6:45 – 8:00 Panel Discussion 8:00 – 9:30 Networking and Vendor Walk

What can you expect? • Expert panel discussions • Networking with clinical, research, and

cannabis industry leaders • Interactive vendor learning opportunities • Event report summary emailed post event • Hors d’oeuvres


27

Virtual Cannabis Center of Excellence (CoE), powered by C3RN


January - June 2018 Event Series Details January 2018 - How can we advance cannabis research?

The opportunities for cannabis cultivation, laboratory, clinical, social, and public health research in Massachusetts

February 2018 - Community first!

Models and best practices for ensuring engagement and equitable access, consumption, and integration in the industry in Massachusetts

March 2018 – Research collaborations from seed to bedside?

Medical cannabis cultivation, clinical care, and research models in Massachusetts April 2018 - The relationship between cannabis and opioids: prevention and treatment

Addressing the opioid epidemic using cannabis as a tool in Massachusetts May 2018 – Connecting through cannabis education and standards?

Creating pathways for multi-sectorial collaboration to advance cannabis science, education, and innovation in Massachusetts

June 2018 – A community-led cannabis research ecosystem

Advancing the medical and adult-use cannabis research agenda in the Commonwealth

Learn More or Sign Up for Updates: http://cannacenterofexcellence.org/register

The virtual Cannabis Center of Excellence (CoE), powered by Cannabis Community Care and Research Network (C3RN), is a group like minded cannabis industry, advocacy, academic,

public health, clinical, patient, policy, and community experts that embrace open-source principles to drive collaborative science in the cannabis industry.

This event series is powered by Cannabis Community Care and Research Network (C3RN)

www.cannaresearchnetwork.com


28

References Cited

1. National Conference of State Legislatures. State Medical Marijuana Laws. 2. Medical Marijuana Patient Numbers - MPP. 3. National Academies of Sciences E. The Health Effects of Cannabis and Cannabinoids :

The Current State of Evidence and Recommendations for Research. 4. Marijuana and Opiates. 2016. http://www.drugpolicy.org/sites/default/files/DPA_Fact

Sheet_Marijuana_and_Opiates_August_2016.pdf. Accessed June 8, 2017. 5. Kral AH, Wenger L, Novak SP, et al. Is cannabis use associated with less opioid use

among people who inject drugs? Drug Alcohol Depend. 2015;153:236-241. doi:10.1016/j.drugalcdep.2015.05.014.

6. Shi Y, Hockenberry JM, Cummings JR, et al. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend. 2017;173:144-150. doi:10.1016/j.drugalcdep.2017.01.006.

7. Bachhuber M, Bradford WD, Butts D, et al. WHAT IS THE OPIOID CRISIS? 8. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic

Pain — United States, 2016. MMWR Recomm Reports. 2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1er.

9. Bradford AC, Bradford WD. Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D. Health Aff (Millwood). 2016;35(7):1230-1236. doi:10.1377/hlthaff.2015.1661.

10. This is Why Medical Marijuana Should Be Covered by Health Insurance - Medical Marijuana, Inc. (OTC: MJNA).

Documents

January 2018 Event Report - Wild Apricot · Phylos Bioscience Kannaway/M3 Consulting Medwell Health and Wellness Center Revolutionary Clinics 8:45 - 9:00 Networking Session Talks